Table 4.
Human leucocyte antigen (HLA)-E gene polymorphisms in relation to selected clinical features in female rheumatoid arthritis (RA) patients.
| HLA-E rs1264457 | HLA-E rs1059510 | |||||
|---|---|---|---|---|---|---|
| 01 : 01 | 01 : 01 | 01 : 03 | 01 : 03 : 01 | 01 : 03 : 01 | 01 : 03 : 02 | |
| 01 : 01 | 01 : 03 | 01 : 03 | 01 : 03 : 01 | 01 : 03 : 02 | 01 : 03 : 02 | |
| DAS28 at baseline | 6·50 (±0·63) | 6·51 (±0·62) | 6·52 (±0·56) | 6·53 (±0·62) | 6·48 (±0·61) | 6·55 (±0·60) |
| DAS28 at week 24 | 3·26 (±1·08) | 3·39 (±1·13) | 3·44 (±1·18) | 3·24 (±1·06) | 3·43 (±1·18) | 3·61 (±1·11) |
| Δ DAS28 | −3·24 (±1·16) | −3·10 (±1·14) | −3·14 (±1·25) | −3·27 (±1·14) | −3·05 (±1·22) | −2·94 (±1·11) |
| CRP at baseline | 20·3 (±18·7) | 25·1 (±43·7) | 16·8 (±18·9) | 17·4 (±16·7) | 27·4 (±45·2) | 14·9 (±19·5) |
| CRP at week 24 | 6·3 (±7·3) | 8·2 (±15·0) | 7·6 (±7·6) | 6·5 (±9·1) | 7·4 (±13·6) | 8·9 (±7·8)* |
| Δ CRP | −13·9 (±17·8) | −17·0 (±40·6) | −9·1 (±21·4) | −10·8 (±16·7) | −20·2 (±43·0) | −6·0 (±22·2)† |
| RF+ | 45 (33%) | 66 (49%) | 25 (18%) | 61 (47%) | 55 (42%) | 15 (11%) |
| Anti-CCP+ | 53 (30%) | 96 (54%) | 29 (16%) | 73 (43%) | 79 (47%) | 16 (10%) |
*
01:03:02|01:03:02 versus 01:03:01| 01:03:01 + 01:03:01| 01:03:02, P = 0·013; 01:03:02|01:03:02 versus 01:03:01| 01:03:01, P = 0·022.
†
01:03:02|01:03:02 versus 01:03:01| 01:03:01 + 01:03:01| 01:03:02, P = 0·009; 01:03:02|01:03:02 versus 01:03:01| 01:03:01, P = 0·020. DAS28 and CRP values represent mean ± standard deviation, RF+ and anti-CCP+ values represent frequencies of RF positive and anti-CCP positive patients. DAS28 = disease activity score 28; CRP = C-reactive protein; anti-CCP = antibodies to cyclic citrullinated peptide.